Breaking News

Recipharm Invests in Single Dose Nasal Platform Capabilities

Services available for full method development, formulation and container closure system, GLP material manufacturing and supply, development stability testing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm, a global CDMO, is expanding its capabilities for its proprietary Unidose Xtra (single dose) nasal delivery platform.   The company has seen greater interest in intranasal drug delivery in pharmaceutical R&D over the last 10 years as it offers advantages over standard systemic delivery systems. The potential benefits of nasal delivery include offering a more favorable patient experience, with targeted delivery resulting in a faster response to the medication.   Recipharm has al...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters